Disclosures: Shuhei Yamamoto: Nothing to Disclose, Takahiro Kodama: Chugai Pharmaceuticals: Speaking and Teaching, Astrazeneca: Speaking and Teaching, Eisai Co Ltd: Speaking and Teaching, Kazuki Maesaka: Nothing to Disclose, Akifumi Kuwano: Nothing to Disclose, kenta Motomura: Nothing to Disclose, Kumiko Shirai: Nothing to Disclose, Akira Doi: Nothing to Disclose, Kazuhiro Murai: Nothing to Disclose, Yuki Tahata: Nothing to Disclose, Yoshinobu Saito: Nothing to Disclose, Hayato Hikita: Nothing to Disclose, Tomohide Tatsumi: Nothing to Disclose, Tetsuo Takehara: Nothing to Disclose 1946 LIPOPHILIC STATIN INCREASES SENSITIVITY FOR LENVATINIB BY SUPPRESSING YAP/TAZ IN HEPATOCELLULAR CARCINOMA CELL LINES AND PATIENT-DERIVED ORGANOIDS Jae Seung Lee 1 Kyung Joo Cho 2 Hye Jung Park 2 Hye Won Lee 1 Mi Na Kim 1 Beom Kyung Kim 1 Do Young Kim 1 Sang Hoon Ahn 1 Jun Yong Park 1 , 1 Yonsei University College of Medicine, 2 Severance Hospital Background: Elevated expression of the transcription factors Yes-associated protein (YAP) and its paralogue, transcriptional co-activator with PDZ-binding motif (TAZ), contributes to drug resistance and adverse prognosis in patients with hepatocellular carcinoma (HCC)
Reconstitution and Dosage Guide As an oral small molecule, 5-Amino-1MQ in research is typically utilized in oral delivery formats
The suggested dose is 24 g per day, taken in divided doses (12 g twice a day) between meals.
10.1158/1078-0432.CCR-12-1099 83 NilssonA.HaanstraJ
